Preclinical models of antipsychotic drug action
The International Journal of Neuropsychopharmacology – June 10, 2013
Source: OpenAlex
Summary
Hallucinogens like Lysergic acid diethylamide (LSD) and Psilocybin, alongside dissociative drugs such as Phencyclidine (PCP), offer crucial insights into Schizophrenia, a critical neuroscience and psychiatry focus. These drugs induce psychosis, mirroring symptoms. Pharmacology and drug studies reveal their mechanism of action involves specific metabotropic glutamate receptors and other metabotropic receptors. Understanding this neurotransmitter receptor influence on behavior is vital for developing new antipsychotic medicine. Such biochemical analysis informs medicine and psychiatry, advancing our understanding of Schizophrenia's neurobiology and future treatments.
Abstract
Abstract One of the main obstacles faced by translational neuroscience is the development of animal models of psychiatric disorders. Behavioural pharmacology studies indicate that psychedelic drugs, such as lysergic acid diethylamide (LSD) and dissociative drugs, such as phencyclidine (PCP), induce in healthy human volunteers psychotic and cognitive symptoms that resemble some of those observed in schizophrenia patients. Serotonin 5-HT2A and metabotropic glutamate 2 receptors have been involved in the mechanism of action of psychedelic and dissociative drugs. Here we review recent advances using LSD-like and PCP-like drugs in rodent models that implicate these receptors in the neurobiology of schizophrenia and its treatment.